Volpara (ASX:VHT) share price pushes higher on record quarterly update

The company provided investors with its latest performance report.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Volpara Health Technologies Ltd (ASX: VHT) share price is climbing today following the release of the company's quarterly report.

At the time of writing, the healthcare technology company's shares are up 1.17% to $1.295.

a smiling doctor looks at her computer screen with medical imaging X-rays on a light screen in the background.

Image source: Getty Images

How did Volpara perform for Q2 FY22?

According to its release, Volpara advised record sales and cash inflows for the 3 months ending 30 September.

In particular, cash receipts from customers totalled NZ$7.1 million (A$6.79 million), an increase of 11% on the previous quarter. Compared against the prior corresponding period, this metric grew 52% — or 68% in constant currency terms.

Subscription-based receipts continued to accelerate, representing more than NZ$6.9 million (A$6.60 million) for the 3 months. This is a jump of 63% year-on-year, or roughly 74% in constant currency.

Net operating cash outflow came to NZ$3.8 million (A$3.63 million), consistent with Q2 FY21. Some material supplier contract renewals, such as its annual insurance program, kept the costs in line.

Volpara noted that it closed the quarter with cash of NZ$25 million (AS23.91) on hand and no debt.

On the Software-as-a-Service (SaaS) front, annual recurring revenue (ARR) stood at US$20.4 million (A$27.24) million. Contracts were signed across the company's full product suite as both standalone sales and platform deals. Many existing customers also increased contracts with Volpara whether by adding on products or expanding use of existing products.

The average revenue per user (ARPU) improved to US$1.46 (A$1.95), up 5% on the prior quarter. Its legacy MRS support contracts were heavily weighted towards the lower ARPU ranges, while its subscription-based products weighted more to the higher ARPUs.

Volpara group CEO Dr Ralph Highnam commented:

Q2 is traditionally our weakest quarter for sales, and yet today we've shown that we've had a record quarter not only for sales but also cash inflows.

…Our job now is to keep that momentum and passion for what we do as we go through the second half of the year, keeping in mind potential winter waves of COVID in the northern hemisphere.

Volpara share price summary

The past 12 months have been a disappointing run for investors, with the company's shares down almost 11%. When looking at year-to-date, its losses are hovering around 9% over the period.

Based on today's price, Volpara presides a market capitalisation of roughly $329 million and has approximately 251.3 million shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended VOLPARA FPO NZ. The Motley Fool Australia owns shares of and has recommended VOLPARA FPO NZ. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

young female doctor with digital tablet looking confused.
Healthcare Shares

Telix shares are tumbling. Is the stock finally at fair value?

Telix's sell-off reflects valuation, competition, and heightened growth expectations.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Why I'd buy Medibank shares for the dividend yield

Medibank is providing investors with very healthy dividends.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Fisher & Paykel Healthcare shares: Earnings outlook upgraded for FY27

Here's what the company expects to report for FY 2027.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Test Only

Pacific Edge FY26: Loss widens but Medicare draft boost lifts outlook

Pacific Edge’s FY26 loss grew, but US Medicare draft coverage for its diagnostic tests supports a more positive outlook going…

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

Why I'd buy CSL, Cochlear, and Pro Medicus shares

These are three ASX healthcare shares I would be happy to own for years.

Read more »

Portrait, confidence and team of doctors in the hospital standing after a consultation or surgery. Success, healthcare and group of professional medical workers in collaboration at a medicare clinic.
Earnings Results

Sonic Healthcare share price in focus on FY26 profit jump and digital push

The healthcare company is paying total dividends of $1.08 per share in FY 2026.

Read more »

A man closely watches a clock.
Healthcare Shares

CSL shares are flying higher. Is it too late to buy?

CSL must now deliver faster earnings growth to justify its rally.

Read more »

Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.
Earnings Results

Telix Pharmaceuticals delivers robust half-year earnings and pipeline progress

The radiopharmaceuticals company has handed down its half-year results this morning.

Read more »